Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 102 and Avastin in Recurrent Malignant Glioma
NCT01113398Phase 2Completed
- Sponsor
- Katy Peters
- Start
- Aug 2010
- Primary completion
- Nov 2014
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of rilotumumab in glioblastoma multiforme (GBM), Gliosarcoma (GS), sponsored by Katy Peters. Started Aug 2010; status: completed.
02
Drugs
rilotumumab
03
Conditions
glioblastoma multiforme (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT01113398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01113398.